Dapagliflozin + sacubitril/valsartan

Dapagliflozin + sacubitril/valsartan has been studied in 3 papers since 2025: 1 observational study in people, 2 in animals; 2 in the past year. The newest paper, Nov 2, 2026: “Therapeutic Effects of Sacubitril/Valsartan and Dapagliflozin on Oxidative Stress and Iron Dysregulation in Monocrotaline-Induced Pulmonary Arterial Hypertension”.

Intervention

3 papers study it7 findingsUpdated

1 new paper in 30 daysSee all 3 papers on dapagliflozin + sacubitril/valsartan

At a glance

The findings reach people, from one lab or study. 3 independent labs in 3 countries.

“the study group showed a marked increase in LVEF (60.3±6.2 vs 54.1±5.7, P < 0.001)”
Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarctionAmerican journal of translational research2025doi:10.62347/qlua3216

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 3 independent labs in 3 countries
  • Funders: Italian Ministry of University and Research and 1 more
  • 2 of 7 findings with company ties
  • Humans1
  • Animals2

What did studies of dapagliflozin + sacubitril/valsartan find?

6

Studies of dapagliflozin + sacubitril/valsartan measured 6 outcomes, among them oxidative stress and ROS signaling, NOS3 and cellular senescence.

Oxidative stress and ROS signaling

downin rats1

1 study
  1. Dapagliflozin + sacubitril/valsartan decreases oxidative stress and ROS signaling in rats (monocrotaline-induced pulmonary arterial hypertension).

    “combined Sacubitril/valsartan and dapagliflozin therapy showed a more consistent antioxidative profile.”

    Animalsmonocrotaline-induced pulmonary arterial hypertensionplasma

    Therapeutic Effects of Sacubitril/Valsartan and Dapagliflozin on Oxidative Stress and Iron Dysregulation in Monocrotaline-Induced Pulmonary Arterial Hypertension

    AHA Scientific Sessions 2026 abstract

More on Oxidative stress and ROS signaling

NOS3

upin rats1

1 study
  1. Dapagliflozin + sacubitril/valsartan increases NOS3 in aged female F344 rats with dysmetabolic aging heart failure.

    “Only the combination therapy significantly enhanced endothelial nitric oxide synthase (eNOS) expression”

    Animalsin aged female F344 rats with dysmetabolic aging heart failureheart45 weeksfemales

    Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction

    Cardiovascular diabetology

More on NOS3

Cellular senescence

downin rats1

1 study
  1. Dapagliflozin + sacubitril/valsartan decreases cellular senescence in aged female F344 rats with dysmetabolic aging heart failure.

    “reduced markers of cellular senescence, including p53 acetylation and p21CIP1”

    Animalsin aged female F344 rats with dysmetabolic aging heart failureheart45 weeksfemales

    Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction

    Cardiovascular diabetology

More on Cellular senescence

Inflammation

downin humans1

1 study
  1. Dapagliflozin + sacubitril/valsartan decreases inflammation in humans (heart failure post emergency PCI for acute myocardial infarction) (113.25±40.55 vs 142.72±31.20 pg/L).

    “in levels of inflammatory factors including (IL-6: 113.25±40.55 vs 142.72±31.20 pg/L, P < 0.001)”

    Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94

    Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction

    American journal of translational research

More on Inflammation

6-minute walk test

upin humans1

1 study
  1. Dapagliflozin + sacubitril/valsartan improves 6-minute walk test in humans (heart failure post emergency PCI for acute myocardial infarction) (447.11±34.08 vs 406.24±31.77 m).

    “better performance in 6MWT (447.11±34.08 vs 406.24±31.77 m, P < 0.001)”

    Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94

    Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction

    American journal of translational research

More on 6-minute walk test

Left ventricular ejection fraction

upin humans1

1 study
  1. Dapagliflozin + sacubitril/valsartan improves left ventricular ejection fraction in humans (heart failure post emergency PCI for acute myocardial infarction) (60.3±6.2 vs 54.1±5.7).

    “the study group showed a marked increase in LVEF (60.3±6.2 vs 54.1±5.7, P < 0.001)”

    Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94

    Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction

    American journal of translational research

What is dapagliflozin + sacubitril/valsartan linked with?

1

Studies link dapagliflozin + sacubitril/valsartan with major adverse cardiac events.

Major adverse cardiac events

downin humans1

1 study
  1. Dapagliflozin + sacubitril/valsartan lowers the risk of major adverse cardiac events in humans (heart failure post emergency PCI for acute myocardial infarction) (9.80% vs 25.58%).

    “patients in the study group demonstrated lower rate of MACE occurrence compared to the control group (9.80% vs 25.58%, P=0.043)”

    Human trialheart failure post emergency PCI for acute myocardial infarction12 weeksn = 94

    Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction

    American journal of translational research

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 12 papers in 12 months